Menu Search
Equities

Merit Medical Systems Inc

MM3:DUS

Merit Medical Systems Inc

Actions
  • Price (EUR)99.50
  • Today's Change1.00 / 1.02%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Merit Medical Systems Inc grew revenues 9.24% from 1.15bn to 1.26bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 26.70% net income growth from 74.52m to 94.41m.
Gross margin46.83%
Net profit margin9.05%
Operating margin11.52%
Return on assets5.73%
Return on equity9.40%
Return on investment6.32%
More ▼

Cash flow in USDView more

In 2023, Merit Medical Systems Inc increased its cash reserves by 872.86%, or 528.59m. Cash Flow from Financing totalled 559.27m or 44.48% of revenues. In addition the company generated 145.15m in cash from operations while cash used for investing totalled 175.35m.
Cash flow per share3.70
Price/Cash flow per share28.11
Book value per share22.71
Tangible book value per share9.47
More ▼

Balance sheet in USDView more

Merit Medical Systems Inc has a Debt to Total Capital ratio of 36.19%, a higher figure than the previous year's 22.96%.
Current ratio5.36
Quick ratio3.82
Total debt/total equity0.5671
Total debt/total capital0.3619
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)14.05
EPS (TTM) vs
TTM 1 year ago		18.62
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.